Generalized Anxiety Disorder Market Size, Growth, Forecast: By Therapeutic Type: Antidepressant, Buspirone, Benzodiazepines; By Therapy Type: Interpersonal Therapy, Behavior Therapy, Cognitive Behavioral Therapy, Mindfulness Based Cognitive Therapy; By Diagnosis; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Generalized Anxiety Disorder Overview 
    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Generalized Anxiety Disorder Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
    5.3    EU-4 and United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
        5.3.1    Germany Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
        5.3.2    France Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
        5.3.3    Italy Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
        5.3.4    Spain Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
    5.4    Japan Generalized Anxiety Disorder Epidemiology Forecast (2017-2032)
6    Generalized Anxiety Disorder Market Overview – 7MM
    6.1    Generalized Anxiety Disorder Market Historical Value (2017-2023) 
    6.2    Generalized Anxiety Disorder Market Forecast Value (2024-2032)
7    Generalized Anxiety Disorder Market Landscape – 7MM
    7.1    Generalized Anxiety Disorder: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Generalized Anxiety Disorder Product Landscape
        7.2.1    Analysis by Treatment Type
        7.2.2    Analysis by Route of Administration
        7.2.3    Analysis by Treatment Type
8    Generalized Anxiety Disorder Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Generalized Anxiety Disorder Market Dynamics
    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Generalized Anxiety Disorder Market Segmentation – 7MM
    11.1    Generalized Anxiety Disorder Market by Therapeutic Type
        11.1.1    Market Overview
        11.1.2    Antidepressant
        11.1.3    Buspirone
        11.1.4    Benzodiazepines 
    11.2    Generalized Anxiety Disorder Market by Therapy Type
        11.2.1    Market Overview
        11.2.2    Interpersonal Therapy
        11.2.3    Behavior Therapy
        11.2.4    Cognitive Behavioral Therapy
        11.2.5    Mindfulness Based Cognitive Therapy 
    11.3    Generalized Anxiety Disorder Market by Diagnosis
        11.3.1    Market Overview
        11.3.2    Deep Brain Stimulation
        11.3.3    Electroconvulsive Therapy
        11.3.4    Transcranial Magnetic
        11.3.5    Stimulation Vagus Nerve
    11.4    Generalized Anxiety Disorder Market by Region
        11.4.1    Market Overview
        11.4.2    United States
        11.4.3    EU-4 and the United Kingdom
            11.4.3.1    Germany
            11.4.3.2    France
            11.4.3.3    Italy
            11.4.3.4    Spain
            11.4.3.5    United Kingdom    
        11.4.4    Japan
12    United States Generalized Anxiety Disorder Market
    12.1    Generalized Anxiety Disorder Market Historical Value (2017-2023) 
    12.2    Generalized Anxiety Disorder Market Forecast Value (2024-2032)
    12.3    Generalized Anxiety Disorder Market by Disease Type
    12.4    Generalized Anxiety Disorder Market by Treatment Type
13    EU-4 and United Kingdom Generalized Anxiety Disorder Market
    13.1    Generalized Anxiety Disorder Market Historical Value (2017-2023) 
    13.2    Generalized Anxiety Disorder Market Forecast Value (2024-2032)
    13.3    Germany Generalized Anxiety Disorder Market Overview
        13.3.1    Generalized Anxiety Disorder Market by Disease Type
        13.3.2    Generalized Anxiety Disorder Market by Treatment Type
    13.4    France Generalized Anxiety Disorder Market Overview
        13.4.1    Generalized Anxiety Disorder Market by Disease Type
        13.4.2    Generalized Anxiety Disorder Market by Treatment Type
    13.5    Italy Generalized Anxiety Disorder Market Overview
        13.5.1    Generalized Anxiety Disorder Market by Disease Type
        13.5.2    Generalized Anxiety Disorder Market by Treatment Type
    13.6    Spain Generalized Anxiety Disorder Market Overview
        13.6.1    Generalized Anxiety Disorder Market by Disease Type
        13.6.2    Generalized Anxiety Disorder Market by Treatment Type
    13.7    United Kingdom Generalized Anxiety Disorder Market Overview
        13.7.1    Generalized Anxiety Disorder Market by Disease Type
        13.7.2    Generalized Anxiety Disorder Market by Treatment Type
14    Japan Generalized Anxiety Disorder Market
    14.1    Generalized Anxiety Disorder Market Historical Value (2017-2023) 
    14.2    Generalized Anxiety Disorder Market Forecast Value (2024-2032)
        14.2.1    Generalized Anxiety Disorder Market by Disease Type
        14.2.2    Generalized Anxiety Disorder Market by Treatment Type
15    Patent Analysis
    15.1    Analysis by Type of Patent
    15.2    Analysis by Publication year
    15.3    Analysis by Issuing Authority
    15.4    Analysis by Patent Age
    15.5    Analysis by CPC Analysis
    15.6    Analysis by Patent Valuation 
    15.7    Analysis by Key Players
16    Grants Analysis
    16.1    Analysis by year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Application
    16.5    Analysis by Funding Institute
    16.6    Analysis by NIH Departments
    16.7    Analysis by Recipient Organization 
17    Clinical Trials Analysis
    17.1     Analysis by Trial Registration Year
    17.2    Analysis by Trial Status
    17.3    Analysis by Trial Phase
    17.4    Analysis by Therapeutic Area
    17.5    Analysis by Geography
18    Funding Analysis
    18.1    Analysis by Funding Instances
    18.2    Analysis by Type of Funding
    18.3    Analysis by Funding Amount
    18.4    Analysis by Leading Players
    18.5    Analysis by Leading Investors
    18.6    Analysis by Geography
19    Partnership and Collaborations Analysis
    19.1    Analysis by Partnership Instances
    19.2    Analysis by Type of Partnership
    19.3    Analysis by Leading Players
    19.4    Analysis by Geography
20    Supplier Landscape
    20.1    Eli Lilly and Company 
        20.1.1    Financial Analysis
        20.1.2    Product Portfolio
        20.1.3    Demographic Reach and Achievements
        20.1.4    Mergers and Acquisition
        20.1.5    Certifications
    20.2    GlaxoSmithKline Pharmaceuticals Limited 
        20.2.1    Financial Analysis
        20.2.2    Product Portfolio
        20.2.3    Demographic Reach and Achievements
        20.2.4    Mergers and Acquisition
        20.2.5    Certifications
    20.3    Pfizer, Inc. 
        20.3.1    Financial Analysis
        20.3.2    Product Portfolio
        20.3.3    Demographic Reach and Achievements
        20.3.4    Mergers and Acquisition
        20.3.5    Certifications
    20.4    Abbott Laboratories 
        20.4.1    Financial Analysis
        20.4.2    Product Portfolio
        20.4.3    Demographic Reach and Achievements
        20.4.4    Mergers and Acquisition
        20.4.5    Certifications
    20.5    Bristol-Myers Squibb 
        20.5.1    Financial Analysis
        20.5.2    Product Portfolio
        20.5.3    Demographic Reach and Achievements
        20.5.4    Mergers and Acquisition
        20.5.5    Certifications
    20.6    Actavis Pharmaceutical Company 
        20.6.1    Financial Analysis
        20.6.2    Product Portfolio
        20.6.3    Demographic Reach and Achievements
        20.6.4    Mergers and Acquisition
        20.6.5    Certifications
    20.7    F. Hoffmann-La Roche 
        20.7.1    Financial Analysis
        20.7.2    Product Portfolio
        20.7.3    Demographic Reach and Achievements
        20.7.4    Mergers and Acquisition
        20.7.5    Certifications
    20.8    Sumitomo Dainippon Pharma 
        20.8.1    Financial Analysis
        20.8.2    Product Portfolio
        20.8.3    Demographic Reach and Achievements
        20.8.4    Mergers and Acquisition
        20.8.5    Certifications
    20.9    MindMed 
        20.9.1    Financial Analysis
        20.9.2    Product Portfolio
        20.9.3    Demographic Reach and Achievements
        20.9.4    Mergers and Acquisition
        20.9.5    Certifications
    20.10    VistaGen Therapeutics, Inc 
        20.10.1    Financial Analysis
        20.10.2    Product Portfolio
        20.10.3    Demographic Reach and Achievements
        20.10.4    Mergers and Acquisition
        20.10.5    Certifications
    20.11    Mitsubishi Chemical Group Corporation
        20.11.1    Financial Analysis
        20.11.2    Product Portfolio
        20.11.3    Demographic Reach and Achievements
        20.11.4    Mergers and Acquisition
        20.11.5    Certifications
    20.12    Sanofi
        20.12.1    Financial Analysis
        20.12.2    Product Portfolio
        20.12.3    Demographic Reach and Achievements
        20.12.4    Mergers and Acquisition
        20.12.5    Certifications
    20.13    Mitsubishi Chemical Group Corporation
        20.13.1    Financial Analysis
        20.13.2    Product Portfolio
        20.13.3    Demographic Reach and Achievements
        20.13.4    Mergers and Acquisition
        20.13.5    Certifications
    20.14    Forest Laboratories, Inc 
        20.14.1    Financial Analysis
        20.14.2    Product Portfolio
        20.14.3    Demographic Reach and Achievements
        20.14.4    Mergers and Acquisition
        20.14.5    Certifications
    20.15    H. Lundbeck A/S
        20.15.1    Financial Analysis
        20.15.2    Product Portfolio
        20.15.3    Demographic Reach and Achievements
        20.15.4    Mergers and Acquisition
        20.15.5    Certifications
21    Generalized Anxiety Disorder Market - Distribution Model (Additional Insight)
    21.1    Overview 
    21.2    Potential Distributors 
    21.3    Key Parameters for Distribution Partner Assessment 
22    Key Opinion Leaders (KOL) Insights (Additional Insight)
23    Company Competitiveness Analysis (Additional Insight)
    23.1    Very Small Companies
    23.2    Small Companies
    23.3    Mid-Sized Companies
    23.4    Large Companies
    23.5    Very Large Companies
24    Payment Methods (Additional Insight)
    24.1    Government Funded
    24.2    Private Insurance
    24.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.